RCN2

Across TCGA pan-cancer cohorts, RCN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RCN2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RCN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RCN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where RCN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.627	0.910	.002	48	view →
CCRCC	OS	Median	II,III,IV	0.228	0.979	.003	30	view →
LUAD	DFS	Tertile	All	0.517	0.735	.030	9	view →
GBM	OS	Median	All	0.772	0.854	.025	6	view →
PDAC	OS	Quartile	II,III,IV	0.794	0.491	.028	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RCN2–HNSC (OS)

Open the HNSC breakdown →